NOW Thai HAART Study

This study has been completed.

Sponsor:

Collaborator:

Rajavithi Biomolecular Research Center

Information provided by:

Rajavithi Hospital

ClinicalTrials.gov Identifier:

NCT00367731

First received: August 22, 2006

Last updated: NA

Last verified: August 2006

History: No changes posted

Purpose

After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.

Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.

Condition	Intervention	Phase
HIV AIDS Neurological Complications	Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)	Phase 4


Study Type:	Observational
Study Design:	Observational Model: Defined Population Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Retrospective/Prospective
Official Title:	Neurological Outcomes With in THAI National HAART Program.

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by Rajavithi Hospital:


Estimated Enrollment:	500
Study Start Date:	January 2005
Estimated Study Completion Date:	September 2006

Eligibility


Ages Eligible for Study:	15 Years and older (Child, Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV/AIDS patients.
Age >15 years.
informed consent

Exclusion Criteria:

Not informed consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00367731

Locations


Thailand
Rajavithi Hospital
Bangkok, Thailand, 10400
Lumpang Hospital
Lumpang, Thailand
Sappasithiprasong Hospital
Ubonratchathani, Thailand

Sponsors and Collaborators

Rajavithi Hospital

Rajavithi Biomolecular Research Center

Investigators


Principal Investigator:	Subsai Kongsaengdao, M.D.	Rajavithi Hospital

More Information


ClinicalTrials.gov Identifier:	NCT00367731 History of Changes
Other Study ID Numbers:	RVH_CER_003
Study First Received:	August 22, 2006
Last Updated:	August 22, 2006
Health Authority:	Thailand: Ministry of Public Health

Keywords provided by Rajavithi Hospital:


HIV AIDS Neurological complications HAART

ClinicalTrials.gov processed this record on September 29, 2016

To Top